<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451646</url>
  </required_header>
  <id_info>
    <org_study_id>05-SMOF-006</org_study_id>
    <nct_id>NCT00451646</nct_id>
  </id_info>
  <brief_title>Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition</brief_title>
  <official_title>A Double-blind, Randomised Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and tolerance of SMOFlipid 20% in comparison
      to a standard lipid emulsion Intralipid 20% in patients requiring long-term parenteral
      nutrition. The safety and tolerance will be evaluated by biochemistry, hematology and
      coagulation variables, vital signs and adverse events. Further objectives to evaluate are the
      influence of SMOFlipid 20% on inflammation processes, the efficacy of anti-oxidative
      properties of vitamin E supplemented to SMOFlipid 20%, and the fatty acid pattern in red
      blood cells and serum.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SMOFlipid 20% assessed by laboratory and clinical parameters (biochemistry, hematology, coagulation), vital signs, adverse events (AEs) as well as inflammation and lipid peroxidation variables</measure>
    <time_frame>day 0, week 2, week 4</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMOFlipid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intralipid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMOF lipid and Intralipid</intervention_name>
    <description>1-2 g, 5-7 days, 28 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In- and out-patients in need of parenteral nutrition due to inability to sustain an
             adequate oral/enteral food intake for at least 4 weeks

          -  Written consent from the subject

        Exclusion Criteria:

          -  Known hypersensitivity to fish-, egg-, soy-, or peanut-protein or to any of the active
             substances or excipients

          -  Known type IV hyperlipidemia, disturbances in lipid metabolism or hypertriglyceridemia

          -  Severe liver insufficiency

          -  Severe blood coagulation disorders

          -  Subjects with chronic stable renal insufficiency defined as S-creatinine value of &gt; 25
             mg/l (200 µmol/l) or receiving dialysis/hemofiltration therapy

          -  General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration

          -  Unstable conditions

          -  Unstable angina pectoris

          -  Acute shock

          -  Chemotherapy within 4 weeks before start of the trial

          -  Chemotherapy during the trial

          -  Subjects for whom the trial treatment is not appropriate

          -  Female patients must be surgically sterile; or postmenopausal for at least two years;
             or if of childbearing potential must have a negative serum pregnancy test and must
             agree to maintain adequate birth control practice during the study.

          -  Participation in another clinical study with an investigational drug or an
             investigational medical device within one month prior to start of study or during the
             study

          -  Prior inclusion in the present study

          -  Any other feature that in the opinion of the investigator should preclude study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Shaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Hospital, Manchester, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore Private Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital, Department of Medical Gastroenterology</name>
      <address>
        <city>Aalborg</city>
        <zip>0 9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Department of Medical Gastroenterology</name>
      <address>
        <city>Copenhagen</city>
        <zip>0 2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy la Garenne</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot, Unite de Nutrition a Domicile Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson Medical Center, Department of Surgery &quot;B&quot;</name>
      <address>
        <city>Petah Tiqwa</city>
        <zip>0 45100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wydzial Lekarski I Katedra Chirurgii Ogolnej</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego</name>
      <address>
        <city>Warsaw</city>
        <zip>00-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>0M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ingrid Mueller</name_title>
    <organization>Fresenius Kabi Deutschland GmbH</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

